Addition of Amlodipine or Valsartan for Improvement of Diastolic Dysfunction Associated with Hypertension
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
BACKGROUND: Hypertensive patients are at increased risk of diastolic dysfunction. The hypothesis of this study was that addition of amlodipine would be superior to valsartan in improving diastolic dysfunction associated with hypertension. METHODS: In this randomized trial, we randomly assigned 104 controlled, hypertensive patients with diastolic dysfunction to receive either amlodipine 2.5 mg or valsartan 40 mg, in addition to antihypertensive therapy. The primary end point was the change in the ratio of early mitral inflow velocity to early mitral annular relaxation velocity (E/E′) from baseline to the 6-month follow-up. Secondary end points included changes in systolic blood pressure (SBP), left ventricular (LV) mass index, and left atrial volume index. RESULTS: SBP decreased significantly from baseline in both treatment groups (p < 0.001). E/E′ decreased significantly from 13.0 ± 2.2 to 12.0 ± 2.7 in the amlodipine arm and from 14.4 ± 4.3 to 12.7 ± 3.7 in the valsartan arm (p < 0.01 in both groups). The change of E/E′ was not significantly different between treatment groups (p = 0.25). There were also no significant between-group differences regarding the changes in SBP, LV mass index, and left atrial volume index. Two patients (3.8%) in the amlodipine group and 1 (16%) in the valsartan group had serious adverse event. CONCLUSIONS: In this randomized trial involving controlled hypertensive patients, addition of amlodipine or valsartan was associated with an improvement of diastolic dysfunction, but the effects on diastolic dysfunction did not differ significantly between the treatment groups.
Abstract
BACKGROUND: Hypertensive patients are at increased risk of diastolic dysfunction. The hypothesis of this study was that addition of amlodipine would be superior to valsartan in improving diastolic dysfunction associated with hypertension. METHODS: In this randomized trial, we randomly assigned 104 controlled, hypertensive patients with diastolic dysfunction to receive either amlodipine 2.5 mg or valsartan 40 mg, in addition to antihypertensive therapy. The primary end point was the change in the ratio of early mitral inflow velocity to early mitral annular relaxation velocity (E/E′) from baseline to the 6-month follow-up. Secondary end points included changes in systolic blood pressure (SBP), left ventricular (LV) mass index, and left atrial volume index. RESULTS: SBP decreased significantly from baseline in both treatment groups (p < 0.001). E/E′ decreased significantly from 13.0 ± 2.2 to 12.0 ± 2.7 in the amlodipine arm and from 14.4 ± 4.3 to 12.7 ± 3.7 in the valsartan arm (p < 0.01 in both groups). The change of E/E′ was not significantly different between treatment groups (p = 0.25). There were also no significant between-group differences regarding the changes in SBP, LV mass index, and left atrial volume index. Two patients (3.8%) in the amlodipine group and 1 (16%) in the valsartan group had serious adverse event. CONCLUSIONS: In this randomized trial involving controlled hypertensive patients, addition of amlodipine or valsartan was associated with an improvement of diastolic dysfunction, but the effects on diastolic dysfunction did not differ significantly between the treatment groups.
참고문헌 (16)
- Levy D, "The progression from hypertension to congestive heart failure", JAMA, 275, pp.1557~1562 (1996)
- Vasan RS, "Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction : prevalence and mortality in a population-based cohort", J Am Coll Cardiol, 33, pp.1948~1955 (1999)
- Bhatia RS, "Outcome of heart failure with preserved ejection fraction in a populationbased study", N Engl J Med, 355, pp.260~269 (2006)
- European Study Group, "How to diagnose diastolic heart failure", Eur Heart J, 19, pp.990~1003 (1998)
- Weber KT, "Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensinaldosterone system", Circulation, 83, pp.1849~1865 (1991)
- Desai A, "Current understanding of heart failure with preserved ejection fraction", Curr Opin Cardiol, 22, pp.578~585 (2007)
- Massie BM, "Irbesartan in patients with heart failure and preserved ejection fraction", N Engl J Med, 359, pp.2456~2467 (2008)
- Solomon SD, "Effect of angiotensin receptor blockade and antihypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction : a randomised trial", Lancet, 369, pp.2079~2087 (2007)
- Solomon SD, "Effect of intensive versus standard blood pressure lowering on diastolic function in patients with uncontrolled hypertension and diastolic dysfunction", Hypertension, 55, pp.241~248 (2010)
- Nagueh SF, "Doppler tissue imaging : a noninvasive technique for evaluation of left ventricular relaxation and estimation of filling pressures", J Am Coll Cardiol, 30, pp.1527~1533 (1997)
- Schiller NB, "Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms", J Am Soc Echocardiogr, 2, pp.358~367 (1989)
- Tapp RJ, "Differential effects of antihypertensive treatment on left ventricular diastolic function : an ASCOT(Anglo-Scandinavian Cardiac Outcomes Trial)substudy", J Am Coll Cardiol, 55, pp.1875~1881 (2010)
- SPRINT Research Group, "A randomized trial of intensive versus standard blood-pressure control", N Engl J Med, 373, pp.2103~2116 (2015)
- Oh JK, "The Echo Manual", pp.120~142 (2007), Lippincott Williams & Wilkins
- Sohn DW, "Assessment of mitral annulus velocity by Doppler tissue imaging in the evaluation of left ventricular diastolic function", J Am Coll Cardiol, 30, pp.474~480 (1997)
- Ommen SR, "Clinical utility of Doppler echocardiography and tissue Doppler imaging in the estimation of left ventricular filling pressures : a comparative simultaneous Doppler-catheterization study", Circulation, 102, pp.1788~1794 (2000)